News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,113 Results
Type
Article (45704)
Company Profile (339)
Press Release (704052)
Multimedia
Podcasts (142)
Webinars (21)
Section
Business (212989)
Career Advice (2201)
Deals (37255)
Drug Delivery (132)
Drug Development (84645)
Employer Resources (178)
FDA (16993)
Job Trends (15683)
News (361452)
Policy (34667)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2648)
Accelerated approval (34)
Adcomms (33)
Allergies (150)
Alliances (52237)
ALS (177)
Alzheimer's disease (1714)
Antibody-drug conjugate (ADC) (340)
Approvals (17232)
Artificial intelligence (552)
Autoimmune disease (164)
Automation (39)
Bankruptcy (378)
Best Places to Work (11845)
BIOSECURE Act (22)
Biosimilars (202)
Biotechnology (195)
Bladder cancer (158)
Brain cancer (60)
Breast cancer (656)
Cancer (4956)
Cardiovascular disease (431)
Career advice (1855)
Career pathing (40)
CAR-T (294)
CDC (50)
Celiac Disease (2)
Cell therapy (778)
Cervical cancer (36)
Clinical research (72154)
Collaboration (1803)
Company closure (5)
Compensation (1188)
Complete response letters (70)
COVID-19 (2810)
CRISPR (97)
C-suite (881)
Cystic fibrosis (149)
Data (6305)
Decentralized trials (2)
Denatured (41)
Depression (139)
Diabetes (521)
Diagnostics (6808)
Digital health (49)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (268)
Drug pricing (218)
Drug shortages (34)
Duchenne muscular dystrophy (238)
Earnings (92384)
Editorial (62)
Employer branding (21)
Employer resources (158)
Events (121521)
Executive appointments (1009)
FDA (20163)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1506)
Gene editing (208)
Generative AI (49)
Gene therapy (633)
GLP-1 (1081)
Government (4892)
Grass and pollen (7)
Guidances (385)
Healthcare (19217)
HIV (60)
Huntington's disease (46)
IgA nephropathy (87)
Immunology and inflammation (280)
Immuno-oncology (62)
Indications (111)
Infectious disease (3094)
Inflammatory bowel disease (197)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (254)
Interviews (344)
IPO (17091)
IRA (58)
Job creations (4176)
Job search strategy (1561)
JPM (69)
Kidney cancer (17)
Labor market (87)
Layoffs (603)
Leadership (38)
Legal (8581)
Liver cancer (93)
Longevity (15)
Lung cancer (669)
Lymphoma (382)
Machine learning (43)
Management (62)
Manufacturing (835)
MASH (174)
Medical device (13909)
Medtech (13962)
Mergers & acquisitions (21248)
Metabolic disorders (1379)
Multiple sclerosis (167)
NASH (20)
Neurodegenerative disease (338)
Neuropsychiatric disorders (97)
Neuroscience (3000)
Neurotech (1)
NextGen: Class of 2026 (6737)
Non-profit (4590)
Now hiring (67)
Obesity (673)
Opinion (307)
Ovarian cancer (168)
Pain (218)
Pancreatic cancer (229)
Parkinson's disease (292)
Partnered (34)
Patents (509)
Patient recruitment (501)
Peanut (60)
People (61460)
Pharmaceutical (100)
Pharmacy benefit managers (33)
Phase 1 (22507)
Phase 2 (31668)
Phase 3 (23721)
Pipeline (5367)
Policy (314)
Postmarket research (2687)
Preclinical (9489)
Press Release (68)
Prostate cancer (243)
Psychedelics (50)
Radiopharmaceuticals (289)
Rare diseases (892)
Real estate (6415)
Recruiting (72)
Regulatory (25776)
Reports (53)
Research institute (2462)
Resumes & cover letters (373)
Rett syndrome (27)
RNA editing (18)
RSV (85)
Schizophrenia (157)
Series A (247)
Series B (196)
Service/supplier (14)
Sickle cell disease (100)
Special edition (27)
Spinal muscular atrophy (163)
Sponsored (43)
Startups (3836)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (100)
The Weekly (99)
Vaccines (1060)
Venture capital (94)
Weight loss (460)
Women's health (92)
Worklife (19)
Date
Today (43)
Last 7 days (575)
Last 30 days (2107)
Last 365 days (30691)
2026 (3577)
2025 (31088)
2024 (36154)
2023 (40936)
2022 (52127)
2021 (56678)
2020 (55113)
2019 (47833)
2018 (36147)
2017 (33581)
2016 (33176)
2015 (39016)
2014 (32966)
2013 (28091)
2012 (30170)
2011 (30876)
2010 (28895)
Location
Africa (828)
Alabama (84)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (43202)
Australia (6853)
California (11402)
Canada (3324)
China (1164)
Colorado (483)
Connecticut (481)
Delaware (342)
Europe (92972)
Florida (1721)
Georgia (356)
Hawaii (3)
Idaho (61)
Illinois (883)
India (68)
Indiana (537)
Iowa (22)
Japan (445)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1404)
Massachusetts (8212)
Michigan (328)
Minnesota (635)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (126)
New Hampshire (78)
New Jersey (3047)
New Mexico (31)
New York (3009)
North Carolina (1520)
North Dakota (8)
Northern California (5555)
Ohio (338)
Oklahoma (22)
Oregon (47)
Pennsylvania (2304)
Puerto Rico (25)
Rhode Island (48)
South America (1197)
South Carolina (67)
South Dakota (1)
Southern California (4434)
Tennessee (177)
Texas (1769)
United States (40628)
Utah (339)
Vermont (1)
Virginia (278)
Washington D.C. (82)
Washington State (930)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
750,113 Results for "mei pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’
September 11, 2025
·
4 min read
Press Releases
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
February 13, 2026
·
5 min read
Press Releases
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
·
6 min read
Press Releases
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
May 14, 2025
·
4 min read
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Biotech Beach
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.
April 10, 2024
·
3 min read
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
Drug pricing
Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.
January 6, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
January 9, 2026
·
9 min read
Business
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma, Inc., a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
May 9, 2024
·
12 min read
1 of 75,012
Next
